Iroquois Capital Nominates Slate Of Highly Qualified Director Candidates For Election At Pharma Cyte’s 2022 Annual Meeting

Dear Fellow PharmaCyte Biotech Stockholders:

As previously communicated, Iroquois Capital Management, LLC (together with its affiliates, “Iroquois”) currently owns approximately 6.1% of the outstanding shares of PharmaCyte Biotech, Inc. (“PharmaCyte” or the “Company”), making us one of the Company’s largest stockholders.

We invested in the Company in Augu…